Designing Durable Remissions in Relapsed AML and Follicular Lymphoma

In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Harry Erba of Duke University and Dr. Sairah Ahmed of the University of Texas MD Anderson Cancer Center on their latest articles published in Blood on durable treatment strategies for relapsed and refractory hematologic malignancies. Dr. Erba discusses "Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia" highlighting the promise of this triplet regimen in a high-risk relapsed setting and delving into the mechanistic differences among menin inhibitors.  Dr. Ahmed discusses "Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL" reviewing the 94% complete response rate, long-term safety profile, and how clinicians can decide whether a patient with relapsed follicular lymphoma is better suited for a bispecific antibody or CAR T-cell therapy.